UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

TBX2 acts as a potent transcriptional silencer of tumour suppressor genes through interaction with the CoREST complex to sustain the proliferation of breast cancers

Nucleic acids research, 2022-06, Vol.50 (11), p.6154-6173

2022

Volltextzugriff (PDF)

NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer

BMC cancer, 2019-04, Vol.19 (1), p.236-236, Article 236

2019

Volltextzugriff (PDF)

BRD7, a Subunit of SWI/SNF Complexes, Binds Directly to BRCA1 and Regulates BRCA1-Dependent Transcription

Cancer research (Chicago, Ill.), 2010-03, Vol.70 (6), p.2538-2547

2010

Volltextzugriff (PDF)

BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

Clinical cancer research, 2007-12, Vol.13 (24), p.7413-7420

2007

Volltextzugriff (PDF)

Defining the molecular evolution of extrauterine high grade serous carcinoma

Gynecologic oncology, 2019-11, Vol.155 (2), p.305-317

2019

Volltextzugriff (PDF)

A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers

Cell communication and signaling, 2024-09, Vol.22 (1), p.454-16, Article 454

2024

Volltextzugriff (PDF)

The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer

Histopathology, 2014-09, Vol.65 (3), p.340-352

2014

Volltextzugriff (PDF)

BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer

The oncologist (Dayton, Ohio), 2007-02, Vol.12 (2), p.142-150

2007

Volltextzugriff (PDF)

Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920906047-1758835920906047

2020

Volltextzugriff (PDF)

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

JNCI : Journal of the National Cancer Institute, 2017-01, Vol.109 (1), p.djw199

2017

Volltextzugriff (PDF)

BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancer

Stem cell reviews, 2012-09, Vol.8 (3), p.982-993

2012

Volltextzugriff (PDF)

A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer

Computational and structural biotechnology journal, 2022-01, Vol.20, p.3359-3371

2022

Volltextzugriff (PDF)

The Role of BRCA1 in the Cellular Response to Chemotherapy

JNCI : Journal of the National Cancer Institute, 2004-11, Vol.96 (22), p.1659-1668

2004

Volltextzugriff (PDF)

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

Oncogene, 2001-09, Vol.20 (43), p.6123-6131

2001

Volltextzugriff (PDF)

BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene

Cancer research (Chicago, Ill.), 2005-11, Vol.65 (22), p.10265-10272

2005

Volltextzugriff (PDF)

BRCA1—A good predictive marker of drug sensitivity in breast cancer treatment?

Biochimica et biophysica acta, 2006-12, Vol.1766 (2), p.205-216

2006

Volltextzugriff (PDF)

Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer‐related cells

Cancer science, 2010-06, Vol.101 (6), p.1354-1360

2010

Volltextzugriff (PDF)

Identification and Validation of an Anthracycline/ Cyclophosphamide-Based Chemotherapy Response Assay in Breast Cancer

JNCI : Journal of the National Cancer Institute, 2014-01, Vol.106 (1), p.djt335

2014

Volltextzugriff (PDF)

Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes

World journal of clinical oncology, 2020-11, Vol.11 (11), p.868-889

2020

Volltextzugriff (PDF)

Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment

Scientific reports, 2016-03, Vol.6 (1), p.23383-23383, Article 23383

2016

Volltextzugriff (PDF)

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis

Cancer research (Chicago, Ill.), 2003-10, Vol.63 (19), p.6221-6228

2003

Volltextzugriff (PDF)

BRCA1 Regulates IFN-γ Signaling through a Mechanism Involving the Type I IFNs

Molecular cancer research, 2007-03, Vol.5 (3), p.261-270

2007

Volltextzugriff (PDF)

Identification and SAR exploration of a novel series of Legumain inhibitors

Bioorganic & medicinal chemistry letters, 2019-06, Vol.29 (12), p.1546-1548

2019

Volltextzugriff (PDF)

BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers

Nucleic acids research, 2013-10, Vol.41 (18), p.8601-8614

2013

Volltextzugriff (PDF)

Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs)

Oncotarget, 2016-08, Vol.7 (34), p.55458-55472

2016

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(98)

Publikationsform

Sprache

Englisch
(109)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

TBX2 acts as a potent transcriptional silencer of tumour suppressor genes through interaction with the CoREST complex to sustain the proliferation of breast cancers

NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer

BRD7, a Subunit of SWI/SNF Complexes, Binds Directly to BRCA1 and Regulates BRCA1-Dependent Transcription

BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

Defining the molecular evolution of extrauterine high grade serous carcinoma

A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers

The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer

BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer

Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancer

A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer

The Role of BRCA1 in the Cellular Response to Chemotherapy

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene

BRCA1—A good predictive marker of drug sensitivity in breast cancer treatment?

Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer‐related cells

Identification and Validation of an Anthracycline/ Cyclophosphamide-Based Chemotherapy Response Assay in Breast Cancer

Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes

Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis

BRCA1 Regulates IFN-γ Signaling through a Mechanism Involving the Type I IFNs

Identification and SAR exploration of a novel series of Legumain inhibitors

BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers

Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs)

Suchergebnisse filtern